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Abstract
The term periodontal disease encompasses a wide variety of chronic inflamma-
tory conditions of the periodontium, including gingivitis and periodontitis. The
gingival disease is an infectious process, which occurs due to the progression of
untreated gingivitis. It is characterized by a destructive inflammatory process that
affects the supporting tissues of the teeth, which causes the loss of the dental
organs. As a result of inflammation, a wide range of cytokines and inflammatory
mediators together contribute to tissue degradation and bone resorption. However,
some molecules that have not been studied in the inflammatory process of this
disease, such as the macrophage migration inhibitory factor (MIF) which is consid-
ered an important cytokine of the innate immune system; it is expressed constitu-
tively in immune and nonimmune cells, and it is released immediately against
bacterial stimuli, hypoxia, and proliferative signals. MIF has been described in some
chronic degenerative, inflammatory, and autoimmune diseases. Previous studies
have described that in murine models of periodontitis, MIF promotes the activation
and differentiation of osteoclasts that could position this cytokine in the
immunopathogenesis of gingival disease in humans.
Keywords: macrophage migration inhibitory factor, cytokine, gingival disease,
periodontitis, osteoclastogenesis
1. Introduction
The periodontium is considered an organ constituted by a group of hard tissues
(alveolar bone and cement) and soft tissues (periodontal ligament and gingiva).
These tissues support the dental organs for a proper function in the oral cavity [1].
The gingiva is a specific oral, physical barrier (Figure 1) [2], which is a dynamic
environment and continuously stimulated by the microbial imbalance, where
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homeostasis is frequently altered, which leads to that entails to an inflammatory
event at the site [3].
Inflammatory cytokines and immune and nonimmune cells play, in the
periodontium, an important defensive role in the gingival barrier [4]. However,
the intimate relation between the epithelial junctions and the surface of the tooth
can be interrupted by routine actions such as chewing and brushing and the
formation of the biofilm, which can cause bacterial translocation [5].
2. Gingiva disease
The interaction between the gingival epithelial cells and the main pathogens
(Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Tannerella
forsythia) [6] (Figure 1) is one of the first events that start with immunological
response at the site, orchestrated by pro-inflammatory mediators as cytokines that
can lead to gingival disease [3].
The gingival disease is defined as an inflammatory disorder initiated on the
surface of the soft tissues, where the persistent inflammation can promote the
destruction of the periodontium [7].
The disease occurs by a complex interaction between the microbial environment
and the immune response of the host, which results in altered bone metabolism and
connective tissue destruction [8]. It has been proposed that periodontopathogens
are necessary but insufficient to promote the destruction of tissues and develop
periodontal lesions because most of the damage is caused by the subversion of the
host immune response [6].
2.1 Immune response in the gingiva
The adhesion and colonization by periodontopathogens in the gingiva trigger
inflammatory through the liberation of endotoxins and bacterial products from
the bacteria [9] which are recognized by the pattern recognition receptor (Toll-like
receptors, cytoplasmic nucleotide oligomerization domain-like, lipopolysaccharide-
binding protein, CD14) expressed in resident cells of the gingiva such as epithelial
cells, fibroblasts, macrophages, neutrophils, and dendritic cells [10].
Figure 1.
Gingiva. The epithelial junction is a specific oral physical barrier.
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The subsequent signal translation activates signaling pathways that promote the
expression of pro-inflammatory cytokines and chemokines [11].
Chemokine, cytokines, and inflammatory mediators such as leukotrienes
increase vascular permeability and the expression of adhesion molecules that stim-
ulate the infiltration of non-resident cells to the tissues such as neutrophils, macro-
phages, and lymphocytes [6]. Therefore, an inflammatory environment is initiated
locally that includes prostaglandins, matrix metalloproteases, complement proteins,
and cytokines [12].
Inflammation is continued by macrophages that increase the concentration of
tumor necrosis factor alpha (TNF-α) and interleukin 1, 6 (IL-1, IL-6); at this
moment more neutrophils are recruited in the furrow to try to control the infection
[3, 11]. If the bacterial infection is not resolved by the inflammation, the antigens
are captured, processed, and shown by antigen-presenting cells that activate naïve
CD4 T lymphocytes at the subtype Th17 [13]. The profile of Th17 lymphocytes
present in the gingival sulcus secretes cytokines such as IL-17 and IL-22 that
enhance inflammation to eliminate extracellular bacteria [11].
The pro-inflammatory microenvironment could compromise the integrity of the
alveolar bone that supports the dental organs which are maintained by the balance
between the reabsorption of the old bone by the osteoclasts and the formation of the
new bone by the osteoblasts; however, in periodontitis (PE), the cycle of bone
remodeling is altered in favor of the resorption [14]. Key effectors in the microen-
vironment of bone resorption involve the molecule triad, receptor activator of
nuclear factor-kappa B ligand (RANKL), receptor activator of nuclear factor-kappa
B (RANK), and decoy receptor osteoprotegerin (OPG) [15, 16]. RANKL, which is
produced by osteoblasts, stromal cells, T cells, and other sources, activates RANK
on the surface of osteoclasts and osteoclast precursors [16]. The process of
Figure 2.
Bone resorption. The osteoclast activity is regulated by the expression and interaction of RANK-RANKL-OPG
[17]. Periodontal disease increased the resorption bone.
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osteoclastogenesis begins by the binding of RANK-RANKL and can be interrupted
by OPG that functions as a decoy receptor that blocks the binding of RANKL to
RANK (Figure 2) [17].
The pro-inflammatory cytokines are proteins that have a principal role in the
control, direction, amplitude, and duration of the immune response. They allow
contact within the immune system and communication with other organs and tissue
systems [8]. Macrophage migration inhibitory factor (MIF) is a proinflammatory
cytokine; MIF is an important mediator of the innate immune response [18]; how-
ever, there are a few studies that describe its participation in PE, for its character-
istics it can lead the environment of the inflammatory response in the disease.
3. Macrophage migration inhibitory factor (MIF)
MIF is a multifunctional protein, constitutively expressed in a wide variety of
immune and nonimmune cells, such as eosinophils, neutrophils, granulocytes,
monocytes/macrophages, B and T lymphocytes; endocrine; endothelial; epithelial;
and neuronal cells [19].
MIF is a monomer of 115 amino acids forming a homotrimer; each has two
antiparallel alpha helices that pack against a four-stranded beta-sheet. Each of the
three monomers is arranged to form a barrel containing a channel that runs through
the center of the protein along a molecule (Figure 3) [20].
MIF is stored in pre-formed and released rapidly in response to the stimulation
from microbial products (LPS), proliferative signals, and hypoxia [18–20], works in
a paracrine and autocrine form, promotes the activation of cells, as well as the
release of pro-inflammatory cytokines, and counteracts the effects of glucocorti-
coids at the sites of inflammation [18].
MIF activates in macrophages functions such as phagocytosis, adherence, motil-
ity and transendothelial migration [19].
Monocytes/macrophages store large amounts of preformed MIF that are released
against stimulation with LPS, glucocorticoids, Gram-positive exotoxins, cytokines,
and pro-inflammatory mediators, which have an important role in the local secre-
tion of MIF during the innate immune response [19, 21].
3.1 MIF and inflammation
The physiological role of MIF is to counteract the inhibitory effects of steroids on
the inflammatory and immune response; MIF is a pro-inflammatory cytokine that
Figure 3.
MIF structure. (a) The folding of the MIF monomer and (b) the folded structure of MIF trimer [18].
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stimulates the release of other cytokines, such as TNF-α, IFN-γ, IL-1β, IL-6, IL-8,
and IL-12 in inflammation [19].
MIF also participate in the modulation of the expression of other pro-
inflammatory molecules, including the same MIF, nitric oxide and cyclooxygenase 2
(COX-2), and prostaglandin 2 (PGE2), perpetuating the inflammatory environ-
ment, by positive feedback to the inflammatory response [22, 23].
MIF plays a critical role in the regulation of the innate immune response,
through the modulation of TLR4. Activation of TLR4 results in the production of
pro-inflammatory mediators, including MIF, which induces the recruitment of
inflammatory cells, including neutrophils [19].
3.2 MIF chemotactic activity
Although MIF was identified for the first time as an inhibitor of macrophage
migration, subsequent studies revealed that in the presence of inflammatory
mediators, it is also capable of leukocyte extravasation [24]. This cytokine can
have a similar function to chemokines while it is in interaction with the
chemokine receptors CXCR4 and CXCR2 to promote the recruitment of inflamma-
tory cells [19].
In this way, MIF participates in the adhesion of monocytes to the vessel wall and
its transendothelial migration [25]. This immobilization of cells to the endothelial
surface is mediated by the action of chemokines that prevent these cells from
continuing their circulation, promoting the immobilization and transmigration of
the cells through the endothelium [26].
3.3 MIF and periodontal disease
The pro-inflammatory, chemoattractant, and osteoclastogenic characteristics of
MIF make it a cytokine with an important role both in the initiation and progression
of periodontal disease (Figure 4).
The studies related to MIF and periodontal disease are few; however,
the existing ones have given the guidelines to introduce this cytokine to its patho-
physiology.
3.3.1 MIF expression in gingival tissue
As mentioned above, MIF is a cytokine produced by immune and nonimmune
cells; therefore the source of MIF in periodontal tissues can be diverse including
inflammatory cells as cells resident in tissues [19].
Figure 4.
MIF in periodontal disease.
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In 2003, the presence of MIF in epithelial cells, keratinocytes, and fibroblasts of
gingival tissue was first described by immunohistochemistry [27], confirming that
this cytokine is located preformed in the cytoplasm of the cell [21], therefore MIF
could participate in homeostatic, proliferative (necessary for the cell), and inflam-
matory functions in the tissue [27].
Likewise, Li et al. evaluated the expression of MIF in gum biopsies of subjects
with PE where they found the presence of MIF in both epithelial strata and in
connective tissue vessels; it was also determined that reconstituted gingival epithe-
lial cells overexpress MIF when performing stimulations with LPS [28]. Therefore,
the expression profile of MIF can be regulated by the periodontal conditions and the
presence of endotoxins that induce its release [21].
3.3.2 MIF in gingival crevicular fluid
The evaluation of MIF in body fluids as a biological indicator has been carried
out in various pathologies. Recently the gingival crevicular fluid (GCF) has received
a lot of attention for being an informative fluid of both physiological and patholog-
ical events in the oral cavity.
In 2009 the concentrations of MIF in GCF of subjects with induced gingivitis
were determined where it is verified that the levels of MIF can be modified in
response to bacterial colonization in the gingival sulcus [29], this being the first
work in describing the cytokine in this fluid.
Another study evaluated the MIF concentrations in GCF of patients with meta-
bolic syndrome with gingivitis. This study found that the group with both patholo-
gies does not present significant differences with the group that presents only
gingivitis; nevertheless, it found differences in comparison with healthy subjects,
and therefore the authors related the increase of MIF directly with the gingival
inflammation and not with the presence of the metabolic syndrome [30].
3.3.3 MIF in saliva and serum
Research on the quantification of MIF in saliva has been increasing in various
pathologies such as oral squamous cell carcinoma [31], in studies evaluating
depressive symptoms [32], and in chronic pelvic pain syndrome [33], among others.
The investigations about MIF serum concentrations are extensive because this
fluid has been used to evaluate MIF in numerous systemic diseases.
In 2017 MIF was evaluated in saliva and serum in aggressive PE, this study was
first to report this cytokine in both fluids in periodontal disease. Their results
showed that the cytokine increased significantly due to the presence of the disease
in both fluids, likewise MIF correlated with clinical diagnostic parameters [34].
Knowing the concentrations of MIF in different fluids in periodontal disease
would provide us the information necessary to know the behavior of the protein at
the local and systemic levels in the presence of this type of entity.
3.3.4 MIF experimental studies
An experimental study in a murine model of PE showed that in MIF / mice,
the absence of MIF decreases the clinical signs of the disease and the recruitment
and phagocytic activity of neutrophils. It also points out that MIF is important in the
control of infection because the lack of the cytokine increases the bacterial load and
decreases the production of inflammatory cytokines in MIF / mice compared to
wild-type mice [35].
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Another study in a murine model of acute apical PE analyzed the coexpression of
MIF and RANKL in periapical lesions induced in mice, where the author associates
that the presence of MIF increases the pro-inflammatory environment that pro-
motes the overexpression of RANKL, the inducer of the direct activation of the
osteoclasts [36].
The osteoclastogenic activity of MIF in PE can also be attributed to the ability of
the cytokine to activate signaling pathways such as NF-kB and NFAT in osteoclast
precursors that initiate differentiation and survival in the cell [37, 38], as well as the
possible chemoattractant faculty of MIF by acting as a ligand for the chemokine
receptor CXCR4 in the recruitment of osteoclast precursor cells [39].
4. Conclusion
In periodontal disease MIF regulates the immune response and can promote soft
tissue degradation and bone resorption.
Due to the few studies about MIF and periodontal disease it is important to
continue doing more research to elucidate the participation of this cytokine in the
immunopathology of this disease.
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Abbreviation
GCF gingival crevicular fluid
MIF macrophage migration inhibiting factor
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RANK receptor activator of nuclear factor-kappa B
RANKL receptor activator of nuclear factor-kappa B ligand
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